Sarepta Therapeutics Inc. (NASDAQ:SRPT)’s share price was up 5% during mid-day trading on Thursday . The stock traded as high as $25.46 and last traded at $25.24, with a volume of 1,036,806 shares trading hands. The stock had previously closed at $24.03.

Several equities research analysts have weighed in on SRPT shares. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, June 3rd. William Blair cut shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 21st. Vetr upgraded shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price objective for the company in a research report on Thursday, June 2nd. Needham & Company LLC raised their price objective on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. Finally, Robert W. Baird restated an “outperform” rating and issued a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 26th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $25.28.

The company’s market cap is $1.16 billion. The firm’s 50-day moving average price is $22.70 and its 200 day moving average price is $18.27.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by $0.16. During the same quarter last year, the company posted ($0.87) EPS. On average, equities research analysts expect that Sarepta Therapeutics Inc. will post ($5.16) EPS for the current year.

A number of hedge funds and institutional investors have modified their holdings of SRPT. Jennison Associates LLC raised its position in shares of Sarepta Therapeutics by 463.6% in the fourth quarter. Jennison Associates LLC now owns 838,629 shares of the company’s stock worth $32,354,000 after buying an additional 689,831 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Sarepta Therapeutics by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 60,108 shares of the company’s stock worth $2,319,000 after buying an additional 358 shares during the period. Rhumbline Advisers raised its position in shares of Sarepta Therapeutics by 16.1% in the fourth quarter. Rhumbline Advisers now owns 47,728 shares of the company’s stock worth $1,841,000 after buying an additional 6,615 shares during the period. Finally, Nationwide Fund Advisors raised its position in shares of Sarepta Therapeutics by 9.2% in the fourth quarter. Nationwide Fund Advisors now owns 29,223 shares of the company’s stock worth $1,127,000 after buying an additional 2,471 shares during the period.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.